These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 17337254)

  • 1. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
    Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
    Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
    Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of retinal peroxisome proliferator-activated receptor gamma in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase.
    Tawfik A; Sanders T; Kahook K; Akeel S; Elmarakby A; Al-Shabrawey M
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):878-84. PubMed ID: 18806296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db-/-) mice.
    Howarth AG; Wiehler WB; Pannirselvam M; Jiang Y; Berger JP; Severson D; Anderson TJ; Triggle CR
    J Pharmacol Exp Ther; 2006 Jan; 316(1):364-70. PubMed ID: 16249369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS.
    Ding H; Hashem M; Triggle C
    Eur J Pharmacol; 2007 Apr; 561(1-3):121-8. PubMed ID: 17292348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M; Wolf G
    Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that nitric oxide inhibits vascular inflammation and superoxide production via a p47phox-dependent mechanism in mice.
    Harrison CB; Drummond GR; Sobey CG; Selemidis S
    Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):429-34. PubMed ID: 19843095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice.
    Gao X; Belmadani S; Picchi A; Xu X; Potter BJ; Tewari-Singh N; Capobianco S; Chilian WM; Zhang C
    Circulation; 2007 Jan; 115(2):245-54. PubMed ID: 17200442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
    Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yasuda O; Ogawa H; Kim-Mitsuyama S
    J Pharmacol Exp Ther; 2010 Oct; 335(1):70-5. PubMed ID: 20651026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-γ activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress.
    Martín A; Pérez-Girón JV; Hernanz R; Palacios R; Briones AM; Fortuño A; Zalba G; Salaices M; Alonso MJ
    J Hypertens; 2012 Feb; 30(2):315-26. PubMed ID: 22179086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4.
    Liang CF; Liu JT; Wang Y; Xu A; Vanhoutte PM
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):777-84. PubMed ID: 23413427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
    Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NO-mediated regulation of NAD(P)H oxidase by laminar shear stress in human endothelial cells.
    Duerrschmidt N; Stielow C; Muller G; Pagano PJ; Morawietz H
    J Physiol; 2006 Oct; 576(Pt 2):557-67. PubMed ID: 16873416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism.
    Ceolotto G; Gallo A; Papparella I; Franco L; Murphy E; Iori E; Pagnin E; Fadini GP; Albiero M; Semplicini A; Avogaro A
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2627-33. PubMed ID: 17916771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins.
    Tesse A; Al-Massarani G; Wangensteen R; Reitenbach S; Martínez MC; Andriantsitohaina R
    J Pharmacol Exp Ther; 2008 Feb; 324(2):539-47. PubMed ID: 18039959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of natriuretic peptide receptor-C attenuates the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats: implication of Gialpha protein.
    Saha S; Li Y; Lappas G; Anand-Srivastava MB
    J Mol Cell Cardiol; 2008 Feb; 44(2):336-44. PubMed ID: 18162186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.